Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock Holdings Decreased by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC trimmed its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 7.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 529,110 shares of the medical instruments supplier's stock after selling 43,505 shares during the quarter. Conestoga Capital Advisors LLC owned approximately 9.78% of Mesa Laboratories worth $68,710,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MLAB. Louisiana State Employees Retirement System raised its stake in Mesa Laboratories by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 2,600 shares of the medical instruments supplier's stock valued at $226,000 after purchasing an additional 100 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Mesa Laboratories by 6.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier's stock valued at $316,000 after buying an additional 175 shares during the last quarter. EntryPoint Capital LLC lifted its stake in shares of Mesa Laboratories by 35.2% during the first quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier's stock valued at $81,000 after buying an additional 193 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Mesa Laboratories during the second quarter worth approximately $26,000. Finally, BNP Paribas Financial Markets grew its stake in Mesa Laboratories by 4.5% in the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier's stock worth $830,000 after acquiring an additional 327 shares during the period. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Mesa Laboratories Trading Up 3.5 %

Shares of MLAB stock traded up $3.96 on Friday, reaching $118.00. 33,538 shares of the stock were exchanged, compared to its average volume of 41,309. The company has a quick ratio of 1.37, a current ratio of 1.94 and a debt-to-equity ratio of 1.38. The stock has a market cap of $638.38 million, a P/E ratio of -2.52 and a beta of 0.85. The firm has a 50 day moving average of $126.44 and a two-hundred day moving average of $113.87. Mesa Laboratories, Inc. has a 1-year low of $82.86 and a 1-year high of $141.17.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.74 by $0.55. The firm had revenue of $58.17 million during the quarter, compared to the consensus estimate of $55.90 million. Mesa Laboratories had a positive return on equity of 18.95% and a negative net margin of 111.89%. On average, research analysts anticipate that Mesa Laboratories, Inc. will post 7.91 EPS for the current year.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 29th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.64 annualized dividend and a yield of 0.54%. Mesa Laboratories's dividend payout ratio is currently -1.38%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MLAB. Evercore ISI raised their price objective on Mesa Laboratories from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. StockNews.com raised Mesa Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, October 26th. Finally, Wells Fargo & Company initiated coverage on shares of Mesa Laboratories in a research note on Tuesday, August 27th. They set an "underweight" rating and a $120.00 price objective for the company.

Insider Transactions at Mesa Laboratories

In related news, CEO Gary M. Owens sold 2,518 shares of the company's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the sale, the chief executive officer now directly owns 45,888 shares of the company's stock, valued at approximately $5,213,794.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Gary M. Owens sold 2,518 shares of the company's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the transaction, the chief executive officer now owns 45,888 shares of the company's stock, valued at $5,213,794.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.40% of the company's stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.